REFERENCES
1. Silva S, Ayoub HH, Johnston C, Atun R, Abu-Raddad LJ. Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: a modeling study. PLoS Med. 2022;19:e1003938.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
3. World Health Organization. World health statistics 2020: monitoring health for the SDGs, sustainable development goals. Available from: https://www.who.int/publications/i/item/9789240005105 [Last accessed on 27 May 2026].
4. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
5. Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239.
6. Wang H, Paulson KR, Pease SA, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399:1513-36.
7. Rolando JC, Melkonian AV, Walt DR. The present and future landscapes of molecular diagnostics. Annu Rev Anal Chem. 2024;17:459-74.
8. Barrangou R, Marraffini LA. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Mol Cell. 2014;54:234-44.
10. Wang KC, Zheng T, Hubbard BP. CRISPR/Cas technologies for cancer drug discovery and treatment. Trends Pharmacol Sci. 2025;46:437-52.
11. Wei L, Wang Z, She Y, Fu H. CRISPR/Cas multiplexed biosensing: advances, challenges, and perspectives. Anal Chem. 2025;97:11943-58.
12. Zhou X, Zhou SJ, Liu J, Wang YX. CRISPR/Cas system targeting RNA and its derivative technology. Yi Chuan. 2025;47:842-860.
13. Cao L, Wang Z, Lei C, Nie Z. Engineered CRISPR/Cas ribonucleoproteins for enhanced biosensing and bioimaging. Anal Chem. 2025;97:5866-79.
14. Navarro C, Díaz MP, Duran P, et al. CRISPR-Cas systems: a functional perspective and innovations. Int J Mol Sci. 2025;26:3645.
15. Zhou J, Li Z, Seun Olajide J, Wang G. CRISPR/Cas-based nucleic acid detection strategies: trends and challenges. Heliyon. 2024;10:e26179.
16. Hryhorowicz M, Lipiński D, Zeyland J. Evolution of CRISPR/Cas systems for precise genome editing. Int J Mol Sci. 2023;24:14233.
17. Wang C, Liu M, Wang Z, Li S, Deng Y, He N. Point-of-care diagnostics for infectious diseases: from methods to devices. Nano Today. 2021;37:101092.
18. Liu R, Han H, Liu F, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020;505:172-5.
19. Laleh S, Ibarlucea B, Stadtmüller M, Cuniberti G, Medina-Sánchez M. Portable microfluidic impedance biosensor for SARS-CoV-2 detection. Biosens Bioelectron. 2023;236:115362.
20. Dai Y, Wu Y, Liu G, Gooding JJ. CRISPR mediated biosensing toward understanding cellular biology and point-of-care diagnosis. Angew Chem Int Ed. 2020;59:20754-66.
21. Chhipa AS, Radadiya E, Patel S. CRISPR-Cas based diagnostic tools: Bringing diagnosis out of labs. Diagn Microbiol Infect Dis. 2024;109:116252.
22. Liang Y, Xie S, Lv Y, et al. A novel single-tube LAMP-CRISPR/Cas12b method for rapid and visual detection of zoonotic Toxoplasma gondii in the environment. Infect Dis Poverty. 2024;13:94.
23. Belo Dos Santos S, Van Tricht C, Lammertyn J, Spasic D. Zoonotic disease detection at the point-of-care: the best of RPA and CRISPR-Cas. Biosens Bioelectron. 2026;293:118139.
24. Mallozzi A, Fusco V, Ragazzini F, Di Bernardo D. A biomolecular circuit for automatic gene regulation in mammalian cells with CRISPR technology. ACS Synth Biol. 2024;13:3917-25.
25. Liu Y, Liu H, Yu G, et al. One-tube RPA-CRISPR Cas12a/Cas13a rapid detection of methicillin-resistant Staphylococcus aureus. Anal Chim Acta. 2023;1278:341757.
26. Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR/Cas system: recent advances and future prospects for genome editing. Trends Plant Sci. 2019;24:1102-25.
27. Kostyusheva A, Brezgin S, Babin Y, et al. CRISPR-Cas systems for diagnosing infectious diseases. Methods. 2022;203:431-46.
28. Hillary VE, Ceasar SA. A review on the mechanism and applications of CRISPR/Cas9/Cas12/Cas13/Cas14 proteins utilized for genome engineering. Mol Biotechnol. 2022;65:311-25.
30. Smith QM, Whittle S, Aramayo RJ, et al. Structural basis of supercoiling-induced CRISPR-Cas9 off-target activity. Nature. 2026;653:627-35.
31. Pardee K, Green AA, Takahashi MK, et al. Rapid, low-cost detection of zika virus using programmable biomolecular components. Cell. 2016;165:1255-66.
32. Tyumentseva M, Tyumentsev A, Akimkin V. CRISPR/Cas9 landscape: current state and future perspectives. Int J Mol Sci. 2023;24:16077.
33. Yan F, Wang W, Zhang J. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9. Cell Biol Toxicol. 2019;35:489-92.
34. Singh M, Bindal G, Misra CS, Rath D. The era of Cas12 and Cas13 CRISPR-based disease diagnosis. Crit Rev Microbiol. 2022;48:714-29.
35. Li X, Li C, Shi C, et al. CRISPR-Cas systems in DNA functional circuits: Strategies, challenges, prospects. Chin Chem Lett. 2025;36:110507.
36. Badon IW, Oh Y, Kim H, Lee SH. Recent application of CRISPR-Cas12 and OMEGA system for genome editing. Mol Ther. 2024;32:32-43.
37. Yu H, Feng M, Liu C, et al. CRISPR-Cas12a2-based rapid and sensitive detection system for target nucleic acid. Int J Biol Macromol. 2025;290:138996.
38. Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360:436-9.
39. Zhuang S, Hu T, Zhou H, et al. CRISPR-HOLMES-based NAD+ detection. Front Bioeng Biotechnol. 2024;12:1355640.
40. Li S, Cheng Q, Wang J, et al. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov. 2018;4:20.
41. Li L, Li S, Wu N, et al. HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation. ACS Synth Biol. 2019;8:2228-37.
42. Scholz P, Thompson J, Crosby KT, et al. RNA-triggered cell killing with CRISPR-Cas12a2. Nature. 2026:10466.
43. Yang H, Patel DJ. Structures, mechanisms and applications of RNA-centric CRISPR-Cas13. Nat Chem Biol. 2024;20:673-88.
44. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438-42.
45. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14:2986-3012.
46. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360:439-44.
47. Harrington LB, Burstein D, Chen JS, et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science. 2018;362:839-42.
48. Aquino-Jarquin G. CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic. Nanomed Nanotechnol Biol Med. 2019;18:428-31.
49. Zhuang S, Bai B, Liu Y. CRISPR-based SNP detection technologies advance from classical methods to cutting-edge innovations. Chem Commun. 2025;61:13345-58.
50. Khmeleva S, Ptitsyn K, Kurbatov L, et al. Biosensing platforms for DNA diagnostics based on CRISPR/Cas nucleases: towards the detection of nucleic acids at the level of single molecules in non-laboratory settings. Biomed Khim. 2024;70:287-303.
51. Sardaru M, Marangoci N, Palumbo R, Roviello GN, Rotaru A. Nucleic acid probes in bio-imaging and diagnostics: recent advances in ODN-based fluorescent and surface-enhanced raman scattering nanoparticle and nanostructured systems. Molecules. 2023;28:3561.
52. Min Y, Hong Y, Kim C, Lee K, Shin Y, Byun J. Split probe-induced protein translational amplification for nucleic acid detection. ACS Appl Bio Mater. 2024;7:8389-97.
53. Chen Z, Luo G, Ren J, et al. Recent advances in and application of fluorescent microspheres for multiple nucleic acid detection. Biosensors. 2024;14:265.
54. Li P, Zhang H, Yang Z, et al. Rapid fluorescent nucleic acid sensing with ultra-thin gold nanosheets. Anal Chim Acta. 2024;1317:342872.
55. Lee I, Kwon S, Sorci M, Heeger PS, Dordick JS. Highly sensitive immuno-CRISPR assay for CXCL9 detection. Anal Chem. 2021;93:16528-34.
56. Shi N, Jia H, Zhang J, et al. Accurate expression of neck motion signal by piezoelectric sensor data analysis. Chin Chem Lett. 2024;35:109302.
57. Wu C, Chen Z, Li C, et al. CRISPR-Cas12a-empowered electrochemical biosensor for rapid and ultrasensitive detection of SARS-CoV-2 delta variant. Nano Micro Lett. 2022;14:159.
58. Wu L, Wang X, Wu C, et al. Ultrasensitive SARS-CoV-2 diagnosis by CRISPR-based screen-printed carbon electrode. Anal Chim Acta. 2022;1221:340120.
59. Dong J, Ma W, Zhou S, et al. Tri-mode CRISPR-based biosensor for miRNA detection: enhancing clinical diagnostics with cross-validation. Anal Chem. 2025;97:10938-46.
60. Wang W, Du H, Dai C, et al. Amplification-free detection of Mycobacterium tuberculosis using CRISPR-Cas12a and graphene field-effect transistors. Nanoscale. 2025;17:4603-9.
61. Yang R, Guan X, Zhang J, et al. Quencher-free CRISPR-based molecular detection using an amphiphilic DNA fluorescence probe. Biosens Bioelectron. 2025;271:117054.
62. Kim J, Hong J, Kim H, et al. CRISPR/Cas13a-assisted amplification-free miRNA biosensor via dark-field imaging and magnetic gold nanoparticles. Sens Diagn. 2024;3:1310-8.
63. Tian T, Qiu Z, Jiang Y, Zhu D, Zhou X. Exploiting the orthogonal CRISPR-Cas12a/Cas13a trans-cleavage for dual-gene virus detection using a handheld device. Biosens Bioelectron. 2022;196:113701.
64. Liu H, Yin H, Xiu L, et al. One-pot isothermal nucleic acid amplification assisted CRISPR/Cas detection technology: challenges, strategies, and perspectives. Adv Sci. 2025;12:e06716.
65. Song J, Cha B, Moon J, et al. Smartphone-based SARS-CoV-2 and variants detection system using colorimetric DNAzyme reaction triggered by loop-mediated isothermal amplification (LAMP) with clustered regularly interspaced short palindromic repeats (CRISPR). ACS Nano. 2022;16:11300-14.
66. Park S, Lee GE, Cho SM, Choi E. Recent applications, future perspectives, and limitations of the CRISPR-Cas system. Mol Ther Nucl Acids. 2025;36:102634.
67. Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38:870-4.
68. Joung J, Ladha A, Saito M, et al. Detection of SARS-CoV-2 with SHERLOCK one-pot testing. N Engl J Med. 2020;383:1492-4.
69. Ibor O, Bassey E, Agu CM, Mirinn KE. Review on gene and cell therapies in prostate cancer treatment: prospects and challenges. J Transl Genet Genom. 2025;9:62-75.
70. Ganbaatar U, Liu C. CRISPR-based COVID-19 testing: toward next-generation point-of-care diagnostics. Front Cell Infect Microbiol. 2021;11:663949.
71. Yin W, Li L, Yang Y, et al. Ultra-sensitive detection of the SARS-CoV-2 nucleocapsid protein via a clustered regularly interspaced short palindromic repeat/Cas12a-mediated immunoassay. ACS Sens. 2024;9:3150-7.
72. Tian Y, Fan Z, Xu L, et al. CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients. Emerg Microbes Infect. 2023;12:e2177088.
73. Sam IK, Chen Y, Ma J, et al. TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosis. J Infect. 2021;83:54-60.
74. Shen Y, Li B, Hao G, et al. A CRISPR/Cas12a-based direct transverse relaxation time biosensor via hydrogel sol-gel transition for Salmonella detection. Food Chem. 2025;470:142693.
75. Patel AK, Singh N, Sachan N, Chandra P. Advancing antibacterial strategies: CRISPR-phage-mediated gene therapy targeting bacterial resistance genes. Curr Gene Ther. 2025:25.
76. Wei H, Li J, Liu Y, et al. Rapid and ultrasensitive detection of Plasmodium spp. parasites via the RPA-CRISPR/Cas12a platform. ACS Infect Dis. 2023;9:1534-45.
77. Zhu H, Zhu D, Li Y, et al. Rapid detection of mutations in the suspected piperaquine resistance gene E415G-exo in Plasmodium falciparum exonuclease via AS-PCR and RAA with CRISPR/Cas12a. Int J Parasitol Drugs Drug Resist. 2024;26:100568.
78. Sidik SM, Huet D, Ganesan SM, et al. A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes. Cell. 2016;166:1423-35.e12.
79. Musunuru K, Grandinette SA, Wang X, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392:2235-43.
80. Park SH, Bao G. CRISPR/Cas9 gene editing for curing sickle cell disease. Transfus Apher Sci. 2021;60:103060.
81. Bai L, Pang Y, Wang T, et al. SPEAR: CRISPR-mediated ultrasensitive, specific and rapid one-pot detection strategy for cancer-related SNPs. Theranostics. 2025;15:3275-88.
82. Etemadzadeh A, Salehipour P, Motlagh FM, et al. An optimized CRISPR/Cas12a assay to facilitate the BRAF V600E mutation detection. J Clin Lab Anal. 2024;38:e25101.
83. Yu Y, Jin M, Yuan W, et al. Engineered crRNA drives RPA-T7-CRISPR/Cas14a cascade for ultrasensitive detection of ctDNA PIK3CA H1047R. Adv Sci. 2025;12:e07126.
84. Sun X, Li X, Jiang H, Shan Y, Zhou S, Wang Z. Accurate diagnosis of colorectal cancer using a combination of lectin-induced recombinase polymerase amplification and CRISPR/Cas12a assay on a point-of-care testing platform with deep learning assistant. Anal Chem. 2025;97:13086-94.
85. Jin L, Zhang J, Nie L, Deng Y, Khana GJ, He N. Chitosan nanoparticles act as promising carriers of microRNAs to brain cells in neurodegenerative diseases. Chin Chem Lett. 2025;36:110774.
86. Wei W, Lin H, Hao T, et al. DNA walker-mediated biosensor for target-triggered triple-mode detection of Vibrio parahaemolyticus. Biosens Bioelectron. 2021;186:113305.
87. Tian Y, Fan Z, Zhang X, et al. CRISPR/Cas13a-assisted accurate and portable hepatitis D virus RNA detection. Emerg Microbes Infect. 2023;12:2276337.
88. Xu J, Liu Y, Zhang J, et al. Single-droplet dual-target quantification of circRNA biomarkers for colorectal cancer screening. Adv Sci. 2025;12:e06159.
89. Fu Y, Zhang P, Chen F, et al. CRISPR detection of cardiac tumor-associated microRNAs. Mol Biol Rep. 2025;52:114.
90. Singh A, Bhatia P. Effective downregulation of BCR-ABL tumorigenicity by RNA targeted CRISPR-Cas13a. Curr Gene Ther. 2021;21:270-7.
91. Bao M, Chen Q, Xu Z, et al. Challenges and opportunities for clustered regularly interspaced short palindromic repeats based molecular biosensing. ACS Sens. 2021;6:2497-522.
92. Bhatia S, Pooja, Yadav SK. CRISPR-Cas for genome editing: Classification, mechanism, designing and applications. Int J Biol Macromol. 2023;238:124054.
93. Kaur R, Gupta S, Chauhan A, Mishra V, Sharma MK, Singh J. Harnessing the power of clustered regularly interspaced short palindromic repeats (CRISPR) based microfluidics for next-generation molecular diagnostics. Mol Biol Rep. 2024;51:896.
94. Ge H, Feng J, Huang L, et al. Development of a highly sensitive, high-throughput and automated CRISPR-based device for the contamination-free pathogen detection. Biosens Bioelectron. 2025;278:117323.
95. Zhang X, Chen H, Fan T, Zhu X, Tan Y, Gao D. A microfluidic biosensor based on multiple signal amplification for rapid and sensitive detection of E. coli O157:H7 and Staphylococcus aureus. Chin Chem Lett. 2026;37:111705.
96. Woolf M, Dignan L, Karas S, et al. Characterization of a centrifugal microfluidic orthogonal flow platform. Micromachines. 2022;13:487.
97. Dignan LM, Karas SM, Mighell IK, Treene WR, Landers JP, Woolf MS. A novel method for inward fluid displacement in centrifugal microdevices for highly integrated nucleic acid processing with long-term reagent storage. Anal Chim Acta. 2022;1221:340063.
98. Chen B, Li Y, Xu F, Yang X. Powerful CRISPR-based biosensing techniques and their integration with microfluidic platforms. Front Bioeng Biotechnol. 2022;10:851712.
99. Zhang Y, Guo Y, Liu G, et al. Portable all-in-one microfluidic system for CRISPR-Cas13a-based fully integrated multiplexed nucleic acid detection. Lab Chip. 2024;24:3367-76.
100. Hu H, Ye Z, Zhang L, et al. A PAM-free and universal CRISPR-Cas12a activation model for ultra-sensitive DNA methylation detection. Chin Chem Lett. 2026;37:111184.
101. Shu T, Yin X, Xiong Q, et al. Lift-CM: an integrated lift-heater centrifugal microfluidic platform for point-of-care pathogen nucleic acid detection using isothermal amplification and CRISPR/Cas12a. Biosens Bioelectron. 2025;274:117178.
102. Li J, Huang H, Song Z, et al. Palm-sized CRISPR sensing platform for on-site mycoplasma pneumoniae detection. Biosens Bioelectron. 2025;281:117458.
103. Hu F, Zhang Y, Yang Y, et al. A rapid and ultrasensitive RPA-assisted CRISPR-Cas12a/Cas13a nucleic acid diagnostic platform with a smartphone-based portable device. Biosens Bioelectron. 2025;280:117428.
104. Avaro AS, Santiago JG. A critical review of microfluidic systems for CRISPR assays. Lab Chip. 2023;23:938-63.
105. Nafian F, Esfahani KS, Hobabi Aghmiuni M, et al. Emerging microfluidic technologies for CRISPR-based diagnostics: an overview. Anal Methods. 2025;17:1962-76.
106. Peleg-Chen D, Shuvali G, Brio L, et al. Microfluidic tool for rapid functional characterization of CRISPR complexes. New Biotechnol. 2022;68:1-8.
107. Cui S, Wang K, Yang Y, Lv X, Li X. An integrated and paper-based microfluidic system employing LAMP-CRISPR and equipped with a portable device for simultaneous detection of pathogens. Anal Bioanal Chem. 2024;417:785-97.
108. Zhao M, Liu X, Ye H, et al. Digital microfluidics actuated multiplexed heterogeneous immunoassay with enhanced automation and efficiency. Chin Chem Lett. 2026;37:111788.
109. Li Z, Hua L, Xie L, Wang D, Jiang X. Automated microfluidic nucleic acid detection platform-integrated RPA-T7-Cas13a for pathogen diagnosis. Anal Chem. 2023;95:6940-7.
110. Wang Y, Long W, He B, Xiong M, Li J, Gao Y. A dual-signal amplification strategy combining DNA-functionalized covalent organic frameworks and CRISPR-Cas12a for early detection of ovarian cancer biomarkers. Chin Chem Lett. 2026;37:112061.
111. Li Y, Zhang J, Chen J, et al. Detection of SARS-CoV-2 based on artificial intelligence-assisted smartphone: A review. Chin Chem Lett. 2024;35:109220.
112. Oboma YI, Ekpenyong B, Charles M. A, Kenneth E.M. Review on gene and cell therapies in prostate cancer treatment: prospects and challenges. J Transl Genet Genom. 2025;9:62-75.
113. Li Z, Ding X, Yin K, Avery L, Ballesteros E, Liu C. Instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using self-contained microfluidic system. Biosens Bioelectron. 2022;199:113865.
114. Tan LL, Mohamad NS. Electrochemical aptamer-based biosensors for sepsis diagnosis: recent advances, challenges, and future perspectives (2020-2025). Biosensors. 2025;15:402.
115. Chen F, Chen L. CRISPR/Cas-mediated macromolecular DNA methylation editing: Precision targeting of DNA methyltransferases in cancer therapy. Int J Biol Macromol. 2025;308:142401.
116. Tian W, Liu T, Niu X, et al. CRISPR/Cas12a-mediated DNAzyme/split-aptamer cascade for label-free detection of site-specific DNA methylation. Biosens Bioelectron. 2025;287:117720.
117. Broto M, Kaminski MM, Adrianus C, et al. Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs. Nat Nanotechnol. 2022;17:1120-6.
118. Liu Y, Zhang S, Jiang K, et al. Near-infrared light responsive upconversion-DNA nanocapsules for remote-controlled CRISPR-Cas9 genome editing. Chin Chem Lett. 2025;36:110282.
119. Choi MY, Li C, Choi J, Choi J. Intracellular biosensors by functional nanomaterial-integrated CRISPR technologies for real-time molecular sensing. Chem Commun. 2026;62:58-70.
120. Zhang Y, Wang T, Zhang J, et al. Formation mechanism for stable system of nanoparticle/protein corona and phospholipid membrane. Chin Chem Lett. 2024;35:108619.
121. Escalona-Noguero C, López-Valls M, Sot B. CRISPR/Cas technology as a promising weapon to combat viral infections. Bioessays. 2021;43:2000315.
122. Xie S, Ji Z, Suo T, Li B, Zhang X. Advancing sensing technology with CRISPR: from the detection of nucleic acids to a broad range of analytes - a review. Anal Chim Acta. 2021;1185:338848.
